Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yasuo Miyoshi
Observed name:
Y. Miyoshi
Institution:
Hyogo Medical University
Observed institutions:
Hyogo Medical University,
The University of Osaka
ORCID:
0000-0001-8535-4008
Observed ORCID:
0000-0001-8535-4008
OpenAlex ID:
A5007690396
Quantitative analysis of estrogen receptor-? and -? messenger RNA expression in breast carcinoma by real-time polymerase chain reaction
2000
·
Kyoko Iwao
, Yasuo Miyoshi
, et al.
·
Cancer
·
76
PDF
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial
2023
·
Eriko Tokunaga
, Yasuo Miyoshi
, et al.
·
The Oncologist
·
11
PDF
The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer
2024
·
Eri Ishikawa
, Takahiro Watanabe
, et al.
·
Breast Cancer Research and Treatment
·
6
PDF
Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE ‐522 Japan Subgroup Analysis
2026
·
Masato Takahashi
, Hirofumi Mukai
, et al.
·
Cancer Science
·
3
PDF
Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer
2026
·
Haruka Kanaoka
, Masayuki Nagahashi
, et al.
·
Breast Cancer
PDF
Abstract PS4-01-24: Cytokine score based on expression levels of multiple cytokines is a prognostic indicator in metastatic breast cancer patients treated with chemotherapy
2026
·
J. Tsuchida
, M. Nagahashi
, et al.
·
Clinical Cancer Research
Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study
2026
·
Yuri Takamatsu
, Yoshiya Horimoto
, et al.
·
International Journal of Clinical Oncology
PDF
Abstract P3-05-17: Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer - A multicenter retrospective study
2025
·
Junichiro Watanabe
, Yoshiya Horimoto
, et al.
·
Clinical Cancer Research
Abstract PO2-06-04: Prospective study on eribulin efficacy in advanced and metastatic breast cancer: changes in TGF-β compared to other standard chemotherapy agents (KBCSG-TR 2018, POTENTIAL)
2024
·
Takahiro Nakayama
, Tersuhiro Yoshinami
, et al.
·
Cancer Research
Abstract PO2-15-09: Immune related cell fraction in peripheral blood and outcomes of advanced breast cancer patients treated with Eribulin
2024
·
Masayuki Nagahashi
, Ayako Bun
, et al.
·
Cancer Research
Abstract P2-11-28: Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients
2023
·
Masayuki Nagahashi
, Chie Toshikawa
, et al.
·
Cancer Research
Abstract P2-20-12: Abundance of tumor-infiltrating lymphocytes is associated with pathologic complete response to neoadjuvant chemotherapy but not with survival in ER-positive/HER2-negative breast cancer
2023
·
Rongrong Wu
, Masayuki Nagahashi
, et al.
·
Cancer Research
Abstract P5-12-02: Germline variants detected by next-generation sequencing-based multigene panel testing in patients with suspected hereditary breast cancer at a University Hospital in Japan
2023
·
Yusa Atake
, Masayuki Nagahashi
, et al.
·
Cancer Research
Abstract P5-02-23: Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count with Clinical Outcomes for Patients with Advanced Breast Cancer in the MONARCH 2 Trial
2023
·
Eriko Tokunaga
, Yasuo Miyoshi
, et al.
·
Cancer Research
Show more works
View as search
Works count:
14
Citation count:
96
H-index:
3
I10-index:
2
Year
Topic
Type